Senseonics Holdings, a medical technology company focused on the development, manufacturing and commercialisation of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced the first European launch of the Eversense 365 CGM system, the world’s first and only one-year CGM. Following CE Mark approval in January, Eversense 365 is now available to the first patients in Sweden, with launches to follow in Germany, Spain, and Italy during the coming weeks.
Eversense products are the only long-term CGM systems available, offering unique features and benefits for people with Type 1 and Type 2 diabetes. The next-generation Eversense 365 doubles sensor lifespan from the previously available Eversense E3, from six months to a full year, and delivers key improvements such as reducing the frequency of calibrations from once daily to once weekly.
Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, said, “This launch of Eversense 365 is a significant breakthrough for diabetes technology in Europe and for Senseonics as a business, as we successfully transitioned to an end-to-end commercial organisation this year. Building on demonstrable commercial momentum in the U.S., European expansion is a key part of our Eversense 365 growth strategy, increasing our total addressable market by over 30 million patients.”
For the first time, certain patients in Europe will now have access to a truly differentiated CGM experience for 365 days with just one sensor. Eversense 365 provides exceptionally accurate glucose data over longer periods of time, so people can focus on managing their diabetes and not their device, minimising common frustrations caused by short-term CGMs:
Longest lasting CGM: The only CGM that lasts a year, while traditional CGMs last 10-15 days and tend to fail early.
No more wasted CGMs: The tiny sensor is designed to rest comfortably under the skin for a full year. Plus, the removable smart transmitter can be taken off and put back on without wasting a CGM.
Alerts that can be trusted: Eversense 365 has exceptional accuracy for one year, with almost no false alerts from compression lows during sleep.
Maximum comfort: The gentle silicone-based adhesives are changed daily and cause almost no skin reactions.
This differentiated approach is proven to empower better diabetes management and improve patient outcomes. Those who have switched to Eversense experience better health outcomes, with meaningful improvements in diabetes management, including better A1C levels and more time in their target glucose range. This is supported by real-world evidence recently presented by Senseonics at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), which demonstrated sustained performance and positive impact of Eversense 365 across a full year period.
